KRAS and non-small cell lung carcinoma: In NSCLC, co-occurrence of mutant KRAS and LKB1 loss has been shown to impact on the urea cycle enzyme CPS1 providing an alternative pool of carbamoyl phosphate to maintain pyrimidine availability thus imposing a growth advantage on lung cancer cells [33].